Repligen Corp (NASDAQ:RGEN) will unveil its latest earnings on Wednesday, June 8, 2011. A biopharmaceutical company, focused primarily on the development of novel therapeutics for radiology and neuropsychiatry.
Repligen Corp Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average analyst is estimating a loss of 3 cents per share, a narrower loss from the year earlier quarter net loss of 5 cents. The consensus estimate is the same as three months ago. For the year, analysts are projecting net income of 4 cents per share, a swing from net loss of 13 cents last year.
Past Earnings Performance: The company is looking to beat analyst estimates for the third quarter in a row. Last quarter, it beat estimates with profit of one cent per share against the mean estimate of 3 cents. In the prior quarter, the company reported net income of 2 cents.
Wall St. Revenue Expectations: On average, analysts predict $6.2 million in revenue this quarter, a rise of 27.3% from the year ago quarter. Analysts are forecasting total revenue of $26.6 million for the year, from last year’s revenue of $21 million.
Revenue has risen the past four quarters. Revenue increased 34.8% to $7.1 million in third quarter of the last fiscal year. The figure rose 38.5% in second quarter from the year earlier and climbed 6.1% in first quarter from the year-ago quarter.
Competitors to Watch: Life Technologies Corp. (NASDAQ:LIFE), Bristol Myers Squibb Co. (NYSE:BMY), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), EntreMed, Inc. (NASDAQ:ENMD), Titan Pharmaceuticals, Inc. (TTNP), Amgen, Inc. (NASDAQ:AMGN), Neuralstem, Inc. (AMEX:CUR), General Electric Company (NYSE:GE), Novavax, Inc. (NASDAQ:NVAX), and Sangamo Biosciences, Inc. (NASDAQ:SGMO).
Recent Price Movement: Over the past three months, the stock price has risen 35 cents (10.1%) from $3.45 on March 8, 2011 to $3.79.
(Sources: YahooFinance and Xignite Financials)
Get Actionable Investing Insights: Check Out Wall St. Cheat Sheet’s newest Feature Trades of the Month!